Journal
BJS OPEN
Volume 4, Issue 4, Pages 678-684Publisher
JOHN WILEY & SONS LTD
DOI: 10.1002/bjs5.50295
Keywords
-
Categories
Funding
- Obel Family Foundation
- Aase and Ejnar Danielsens Foundation
- Augustinus Foundation
- L. F. Foghts Foundation
Ask authors/readers for more resources
Background This study aimed to evaluate the effect of perioperative supplementation with omega-3 fatty acids (n-3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery. Methods Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized to either an n-3 FA-enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control) for 7 days before and after surgery. Outcome measures, including postoperative complications, 3-year cumulative incidence of local or metastatic colorectal cancer recurrence and 5-year overall survival, were compared between the groups. Results Of 148 patients enrolled in the study, 125 (65 patients receiving n-3 FA-enriched ONS and 60 receiving standard ONS) were analysed. There were no differences in postoperative complications after surgery (P = 0 center dot 544). The risk of disease recurrence at 3 years was similar (relative risk 1 center dot 66, 95 per cent c.i. 0 center dot 65 to 4 center dot 26).The 5-year survival rate of patients treated with n-3 FA was 69 center dot 2 (95 per cent c.i. 56 center dot 5 to 78 center dot 9) per cent, compared with 81 center dot 7 (69 center dot 3 to 89 center dot 4) per cent in the control group (P = 0 center dot 193). After adjustment for age, stage of disease and adjuvant chemotherapy, n-3 FA was associated with higher mortality compared with controls (hazard ratio 1 center dot 73, 95 per cent c.i. 1 center dot 06 to 2 center dot 83; P = 0 center dot 029). The interaction between n-3 FA and adjuvant chemotherapy was not statistically significant. Conclusion Perioperative supplementation with n-3 FA did not confer a survival benefit in patients undergoing colorectal cancer surgery. n-3 FA did not benefit the subgroup of patients treated with adjuvant chemotherapy or decrease the risk of disease recurrence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available